{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:02:28Z","timestamp":1791946948651,"version":"4.3.4"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.leukres.2023.107429","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T21:32:29Z","timestamp":1700688749000},"page":"107429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell transplant in patients with acute myeloid leukemia failing conventional intensive chemotherapy"],"prefix":"10.1016","volume":"136","author":[{"given":"Michael","family":"Ashby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tse-Chieh","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ing Soo","family":"Tiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafqat","family":"Inam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushrut","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Vassili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong Chyn","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Supplement 1","key":"10.1016\/j.leukres.2023.107429_bib1","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-113036","article-title":"Mitoxantrone, etoposide and cytarabine (MEC) can induce deep complete remission and is an effective bridge therapy to allotransplantation (SCT) in refractory\/relapsed acute myeloid leukemia (AML) patients","volume":"132","author":"Marconi","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2023.107429_bib2","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3109\/10428194.2012.713479","article-title":"Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse","volume":"54","author":"Fong","year":"2013","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2023.107429_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010022","article-title":"Venetoclax in relapsed\/refractory acute myeloid leukemia: are supporting evidences enough","volume":"14","author":"Brancati","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.leukres.2023.107429_bib4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.leukres.2023.107429_bib5","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2023.107429_bib6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107429_bib7","doi-asserted-by":"crossref","unstructured":"Sartor C., Brunetti L., Audisio E., et al. A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure. British Journal of Haematology. n\/a(n\/a)doi:https:\/\/doi.org\/10.1111\/bjh.18887.","DOI":"10.1111\/bjh.18887"},{"issue":"12","key":"10.1016\/j.leukres.2023.107429_bib8","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/j.bbmt.2020.08.027","article-title":"Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myelogenous leukemia","volume":"26","author":"Sandhu","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.leukres.2023.107429_bib9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2020-143002","article-title":"Hypomethylating agents in combination with venetoclax as a bridge to allogeneic transplant in acute myeloid leukemia","volume":"136","author":"Kennedy","year":"2020","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.leukres.2023.107429_bib10","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1080\/10428194.2021.1966788","article-title":"Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant","volume":"62","author":"Bewersdorf","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2023.107429_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221081637","article-title":"A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed\/refractory acute myeloid leukemia (AML)","volume":"13","author":"Park","year":"2022","journal-title":"Ther. Adv. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2023.107429_bib12","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/bjh.16722","article-title":"Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia","volume":"192","author":"Tiong","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.leukres.2023.107429_bib13","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2023.107429_bib14","author":"Stelljes","year":"2022","journal-title":"2022 ASH Annu. Meet. Exhib."},{"issue":"12","key":"10.1016\/j.leukres.2023.107429_bib15","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262300694X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262300694X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:04:20Z","timestamp":1758935060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521262300694X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":15,"alternative-id":["S014521262300694X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107429","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell transplant in patients with acute myeloid leukemia failing conventional intensive chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107429"}}